CoreyASiegelMD
Gastroenterology • Lebanon, NHAdvanced Endoscopic Interventional, Inflammatory Bowel Disease
Associate Professor, Medicine, Geisel School of Medicine
Dr. Siegel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon, NH 03756
Education & Training
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Gastroenterology, 2002 - 2005- Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 1998 - 2002
Tufts University School of MedicineClass of 1998
Massachusetts General HospitalFellowship, Inflammatory Bowel Disease
The Dartmouth Institute for Health Policy and Clinical PracticeMS, Evaluative Clinical Science
Certifications & Licensure
VT State Medical License 2018 - 2026
ME State Medical License 2018 - 2025
NH State Medical License 2001 - 2025- American Board of Internal Medicine Gastroenterology
Awards, Honors, & Recognition
- Top Doctor New Hampshire Magazine, 2017
- Humanitarian of the Year Crohn's and Colitis Foundation, 2014
- America's Top Doctors Castle Connolly, 2010-2014
- Join now to see all
Clinical Trials
- IBD-OPERA Database, UC Protocol Start of enrollment: 2012 Oct 01
- OPERA Database - Crohn's Protocol Start of enrollment: 2012 Oct 01
- Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease Start of enrollment: 2014 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsTwo-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.Bruce E Sands, Geert D'Haens, David B Clemow, Peter M Irving, Jordan T Johns
Inflammatory Bowel Diseases. 2024-12-05 - Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT-UC C...Parambir S Dulai, Lauren Balmert Bonner, Charlotte Sadler, Laura E Raffals, Gursimran Kochhar
Alimentary Pharmacology & Therapeutics. 2024-12-01 - 7 citationsThe Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated Disease.Akhilesh Swaminathan, James M Fulforth, Chris M Frampton, Grace M Borichevsky, Thomas C Mules
Inflammatory Bowel Diseases. 2024-11-04
Journal Articles
- Systems-Based Strategies to Consider Treatment Costs in Clinical PracticeEric D Shah, Corey A Siegel, Clinical Gastroenterology and Hepatology
- Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumLeah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
- Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY ConsortiumGursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature
- Join now to see all
Authored Content
- Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered CareOctober 2018
Press Mentions
Dartmouth Health and Geisel Receives More Than $14 Million Estate Gift to Transform the Future of Digestive HealthOctober 25th, 2024- It’s ‘Telehealth vs. No Care’: Doctors Say Congress Risks Leaving Patients VulnerableJanuary 31st, 2023
- Takeda Launches Prognostic Crohn's Disease Blood TestSeptember 14th, 2022
- Join now to see all
Grant Support
- Risk Communication In Crohn'S DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2012
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
